Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype

Fangyuan Shao; Heng Sun; Chu-Xia Deng

doi:10.18632/oncotarget.20274

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype

Fangyuan Shao, Heng Sun and Chu-Xia Deng _

PDF | HTML | How to cite

Oncotarget. 2017; 8:73329-73344. https://doi.org/10.18632/oncotarget.20274

Metrics: PDF 5646 views | HTML 8471 views | ?

Abstract

Fangyuan Shao1, Heng Sun1 and Chu-Xia Deng1

1Faculty of Health Sciences, University of Macau, Macau SAR, China

Correspondence to:

Chu-Xia Deng, email: [email protected]

Keywords: cancer therapy, TNBC subtype, CSCs, drug resistance, cancer targets

Received: May 10, 2017 Accepted: August 06, 2017 Published: August 16, 2017

ABSTRACT

Triple-negative breast cancer (TNBC) is an aggressive subgroup of human breast cancer, which is characterized as estrogen receptor (ER) negative, progesterone receptor (PR) negative, and human epidermal growth factor receptor 2 (HER2) negative. TNBC is the most difficult breast cancer subgroup to treat, due to its unresponsiveness to current clinical targeted therapies, high rate of recurrence, and poor prognosis. Thus, there is an urgent medical need to identify therapeutic targets and develop more effective stratified medicine for the treatment of TNBC. Here we review the potential therapeutic targets for TNBC based on its intrinsic subtype. We also review the aberrant activated signals found in different subgroups of TNBC, including androgen receptor (AR) and PI3K/AKT/mTOR, Notch, Wnt/β-catenin, Hedge-hog, and TGF-β signaling pathways, which play essential roles in multiple development stages of TNBC. The careful analysis of these signaling pathways and therapeutic targets would have significant impact on the drug development and clinical trials, leading to effective therapies for this deadly disease.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20274

Publication Alerts

Reviews:

Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype

Abstract